The Quantellect read.As of Nov 19, 2026, 19 active firms cover Elevance Health Inc: 14 rate it Buy or better, 5 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $360.00 to $498.00, so the covering firms are broadly aligned. The average target of $443.74 sits 14% above the current $388.12. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $12.32 next quarter toward $30.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS19 active firms
Buy
Strong Buy00%
Buy1474%
Neutral526%
Sell00%
Strong Sell00%
Based on 19 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$443.74
+14.3% upside
Average target across 19 active firms as of Nov 19, 2026 vs $388.12 current
Highest Target$498.00
Average Target$443.74
Lowest Target$360.00
Detailed analyst forecasts for ELV
Showing 1–19 of 19 named analysts shown · 19 active firms in the rating projection
As of Nov 19, 2026, 14 of 19 active firms rate ELV a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ELV EPS & revenue forecast
EPS · NEXT QUARTER
$12.32
Range $8.69 – $13.23 · 14 analysts · -2% YoY
Next period, 14 analysts expect Elevance Health Inc to earn $12.32 a share (range $8.69 – $13.23), versus $12.58 a year earlier. Full-year consensus is $29.14, growing to $30.29 the year after.
REVENUE · NEXT QUARTER
$50.1B
Range $49.3B – $51.1B · 14 analysts · +1% YoY
Revenue is expected to reach $50.1B (range $49.3B – $51.1B), +1.1% year-over-year. Full-year consensus is $198.8B, rising to $203.7B next year.
Top analysts covering Elevance Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELV.
#1
Stephen Baxter
Wells Fargo · Rank #63
Buy
$473.00+21.9% to target
Overall win rate
47%
+ Follow
#2
Erin Wright
Morgan Stanley · Rank #81
Neutral
$449.00+15.7% to target
Overall win rate
55%
+ Follow
#3
DM
David Macdonald
Truist Securities · Rank #111
Buy
$500.00+28.8% to target
Overall win rate
50%
+ Follow
#4
Ben Hendrix
RBC Capital · Rank #150
Neutral
$455.00+17.2% to target
Overall win rate
44%
+ Follow
#5
Sarah James
Cantor Fitzgerald · Rank #159
Buy
$450.00+15.9% to target
Overall win rate
37%
+ Follow
ELV stock forecast FAQ
What is ELV's average 12-month price target?+
The 19 active firms with a live target average $443.74 for Elevance Health Inc over the next 12 months, ranging from a $498.00 high to a $360.00 low, as of Nov 19, 2026.
Is ELV stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 19 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 5 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ELV?+
The Street-high target is $498.00 (Deutsche Bank), and the Street-low is $360.00 (Evercore ISI Group). The average of all 19 active-firm targets is $443.74.
How many active Wall Street firms cover ELV?+
19 active firms have a recognized rating on Elevance Health Inc as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ELV?+
Among analysts who currently cover ELV, Stephen Baxter of Wells Fargo has the strongest overall Quantellect track record (Rank #63). Their current call is Buy with a $473.00 target.
What is Elevance Health Inc's projected EPS for next quarter?+
The consensus estimate is $12.32 per share (range $8.69 – $13.23) across 14 analysts. Full-year EPS is projected at $29.14, rising to $30.29 the following year.
How much revenue is Elevance Health Inc expected to report next quarter?+
Consensus revenue is $50.1B (range $49.3B – $51.1B). Full-year revenue is projected at $198.8B, growing to $203.7B next year.
Have analysts been upgrading or downgrading ELV lately?+
As of Nov 19, 2026, 14 of 19 active firms rate ELV a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.